# A Case of Orofacial Granulomatosis Treated With Intravenous Rituximab

## TL;DR

A 32-year-old woman with a chronic lip and face swelling condition improved after treatment with rituximab when other drugs failed.

## Contribution

Presents a successful case of rituximab treatment for refractory orofacial granulomatosis.

## Key findings

- The patient showed a 50% reduction in swelling after six months of rituximab treatment.
- Conventional therapies like prednisolone, azathioprine, and HCQ were ineffective in this case.
- Rituximab is suggested as a promising alternative for treatment-resistant orofacial granulomatosis.

## Abstract

Orofacial granulomatosis (OFG) encompasses a range of conditions marked by granuloma formation in the oral and perioral tissues. We report a 32-year-old female with asymptomatic swelling of the lower lip, buccal mucosa, and lower face, accompanied by difficulty in swallowing over a period of one year. A biopsy indicated OFG. The patient had an inadequate response to a combination of oral prednisolone, azathioprine, and hydroxychloroquine (HCQ). She was treated with three doses of injection rituximab resulting in a 50% reduction in swelling after six months. This case report aims to highlight the challenges of treating OFG, recommending rituximab as a promising therapeutic option, particularly when conventional treatments fail. Further research into biologics for this condition is warranted.